The adenosine pathway component CD39 is undergoing evaluation in a phase II trial for neoadjuvant and adjuvant treatment with IPH520 (anti-CD39) combined with durvalumab and chemotherapy in treatment-naïve, resectable, early-stage NSCLC (NCT05742607). This evidence concerns the gene ENTPD1 and non-small cell lung carcinoma.